Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.53
AVEO's Cash to Debt is ranked higher than
63% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. AVEO: 2.53 )
AVEO' s 10-Year Cash to Debt Range
Min: 1.54   Max: 9.15
Current: 2.53

1.54
9.15
Equity to Asset 0.29
AVEO's Equity to Asset is ranked higher than
56% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AVEO: 0.29 )
AVEO' s 10-Year Equity to Asset Range
Min: -3.21   Max: 0.76
Current: 0.29

-3.21
0.76
F-Score: 2
Z-Score: -10.43
M-Score: 7.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -278.35
AVEO's Operating margin (%) is ranked higher than
65% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. AVEO: -278.35 )
AVEO' s 10-Year Operating margin (%) Range
Min: -8035.89   Max: 20.59
Current: -278.35

-8035.89
20.59
Net-margin (%) -290.99
AVEO's Net-margin (%) is ranked higher than
65% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. AVEO: -290.99 )
AVEO' s 10-Year Net-margin (%) Range
Min: -8277.57   Max: 18.59
Current: -290.99

-8277.57
18.59
ROE (%) -111.72
AVEO's ROE (%) is ranked higher than
57% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. AVEO: -111.72 )
AVEO' s 10-Year ROE (%) Range
Min: -116.49   Max: 20.76
Current: -111.72

-116.49
20.76
ROA (%) -49.26
AVEO's ROA (%) is ranked higher than
64% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. AVEO: -49.26 )
AVEO' s 10-Year ROA (%) Range
Min: -88.25   Max: 13.74
Current: -49.26

-88.25
13.74
ROC (Joel Greenblatt) (%) -336.35
AVEO's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. AVEO: -336.35 )
AVEO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1669.78   Max: 678.74
Current: -336.35

-1669.78
678.74
Revenue Growth (3Y)(%) -55.50
AVEO's Revenue Growth (3Y)(%) is ranked higher than
59% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. AVEO: -55.50 )
AVEO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -55.5
Current: -55.5

» AVEO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

AVEO Guru Trades in Q1 2014

Steven Cohen 500,000 sh (New)
Seth Klarman 3,829,350 sh (unchged)
Chuck Royce Sold Out
Jim Simons 1,275,453 sh (-1.82%)
Paul Tudor Jones 106,701 sh (-2.20%)
» More
Q2 2014

AVEO Guru Trades in Q2 2014

George Soros 49,076 sh (New)
Jim Simons 1,343,488 sh (+5.33%)
Paul Tudor Jones 106,701 sh (unchged)
Seth Klarman 3,829,350 sh (unchged)
» More
Q3 2014

AVEO Guru Trades in Q3 2014

Seth Klarman 3,829,350 sh (unchged)
George Soros Sold Out
Paul Tudor Jones 99,319 sh (-6.92%)
Jim Simons 591,700 sh (-55.96%)
» More
Q4 2014

AVEO Guru Trades in Q4 2014

Jim Simons 675,800 sh (+14.21%)
Seth Klarman Sold Out
Seth Klarman Sold Out
Paul Tudor Jones 88,219 sh (-11.18%)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.60
AVEO's P/B is ranked higher than
80% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. AVEO: 3.60 )
AVEO' s 10-Year P/B Range
Min: 0.87   Max: 22.16
Current: 3.6

0.87
22.16
P/S 4.10
AVEO's P/S is ranked higher than
90% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. AVEO: 4.10 )
AVEO' s 10-Year P/S Range
Min: 0.64   Max: 111.5
Current: 4.1

0.64
111.5
EV-to-EBIT -0.79
AVEO's EV-to-EBIT is ranked lower than
52% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AVEO: -0.79 )
AVEO' s 10-Year EV-to-EBIT Range
Min: -8.1   Max: 16.9
Current: -0.79

-8.1
16.9
Current Ratio 1.47
AVEO's Current Ratio is ranked higher than
57% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. AVEO: 1.47 )
AVEO' s 10-Year Current Ratio Range
Min: 1.47   Max: 6.77
Current: 1.47

1.47
6.77
Quick Ratio 1.47
AVEO's Quick Ratio is ranked higher than
59% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. AVEO: 1.47 )
AVEO' s 10-Year Quick Ratio Range
Min: 1.47   Max: 6.77
Current: 1.47

1.47
6.77
Days Sales Outstanding 47.15
AVEO's Days Sales Outstanding is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. AVEO: 47.15 )
AVEO' s 10-Year Days Sales Outstanding Range
Min: 3.19   Max: 390.8
Current: 47.15

3.19
390.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 36.00
AVEO's Price/Net Cash is ranked higher than
66% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 87.00 vs. AVEO: 36.00 )
AVEO' s 10-Year Price/Net Cash Range
Min: 2.26   Max: 21
Current: 36

2.26
21
Price/Net Current Asset Value 18.00
AVEO's Price/Net Current Asset Value is ranked higher than
70% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. AVEO: 18.00 )
AVEO' s 10-Year Price/Net Current Asset Value Range
Min: 1.81   Max: 7.86
Current: 18

1.81
7.86
Price/Tangible Book 3.70
AVEO's Price/Tangible Book is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. AVEO: 3.70 )
AVEO' s 10-Year Price/Tangible Book Range
Min: 1.2   Max: 14.66
Current: 3.7

1.2
14.66
Price/Median PS Value 1.00
AVEO's Price/Median PS Value is ranked higher than
92% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. AVEO: 1.00 )
AVEO' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 11.44
Current: 1

0.58
11.44
Earnings Yield (Greenblatt) -120.60
AVEO's Earnings Yield (Greenblatt) is ranked lower than
61% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. AVEO: -120.60 )
AVEO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -120.6   Max: 48134.7
Current: -120.6

-120.6
48134.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company unique insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 29 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
comment on AVEO Mar 16 2013 
comment on AVEO Mar 16 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 15 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 24 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Other Events Mar 19 2015
AVEO PHARMACEUTICALS INC Financials Mar 12 2015
AVEO Pharmaceuticals (AVEO) Stock Higher Today After Analyst Upgrade Mar 09 2015
AVEO Up on Pipeline News, Q4 Loss Narrower than Expected - Analyst Blog Mar 09 2015
AVEO Oncology upgraded by RBC Capital Mkts Mar 09 2015
10-K for AVEO Pharmaceuticals, Inc. Mar 08 2015
AVEO Pharmaceuticals Soars On Phase II Results Vs. Avastin Mar 06 2015
AVEO Oncology Biomarker Analysis from Phase 2 Clinical Study of Tivozanib in Patients with Advanced... Mar 06 2015
AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib... Mar 06 2015
AVEO Oncology Reports Full Year 2014 Financial Results Mar 06 2015
AVEO PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 06 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Mar 06 2015
AVEO Oncology Reports Full Year 2014 Financial Results Mar 06 2015
AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS with Tivozanib... Mar 06 2015
Regulators Want Drug Companies to Be Honest About FDA Mar 04 2015
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 27 2015
AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker... Feb 27 2015
AVEO Oncology to Host Conference Call to Discuss Presentation of Final Results and Biomarker... Feb 27 2015
Aveo Pharmaceuticals loses position in The Baupost Group Feb 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK